Anupam Rama
Stock Analyst at JP Morgan
(3.61)
# 805
Out of 5,056 analysts
288
Total ratings
44.83%
Success rate
7.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Overweight | $53 → $52 | $31.40 | +65.61% | 11 | Nov 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $26 → $27 | $10.14 | +166.40% | 5 | Nov 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $76 → $77 | $65.65 | +17.29% | 12 | Nov 7, 2025 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $18 → $19 | $9.27 | +105.07% | 14 | Nov 6, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $13 → $11 | $4.52 | +143.36% | 9 | Nov 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $40 → $36 | $19.76 | +82.19% | 18 | Nov 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $171 → $179 | $146.88 | +21.87% | 19 | Nov 3, 2025 | |
| KOD Kodiak Sciences | Upgrades: Overweight | $15 → $24 | $19.68 | +21.95% | 8 | Oct 24, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Overweight | $74 → $79 | $31.54 | +150.48% | 11 | Oct 23, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $30 → $44 | $34.23 | +28.54% | 8 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $8.86 | +24.15% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $13 → $55 | $29.55 | +86.13% | 9 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $105.60 | +89.39% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $37 | $32.40 | +14.20% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.01 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $17 | $12.59 | +35.03% | 6 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $29 | $8.45 | +243.20% | 5 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $17.80 | +34.87% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $33.59 | +138.17% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $33.18 | +252.62% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $41 | $17.12 | +139.49% | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $21.75 | +134.54% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $35.65 | +23.42% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $40.52 | -1.28% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $98.70 | +26.65% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.70 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.69 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.23 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.77 | +370.16% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $5.68 | +1,484.51% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $11.69 | +2,039.50% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.68 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $65.65 | -11.65% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $17.52 | -31.51% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $5.70 | +549.69% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $85.09 | -35.36% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $2.52 | +1,013.32% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $43.84 | +23.18% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.70 | +6,328.57% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $18.89 | +42.93% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $449.99 | -69.55% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $8.47 | +466.71% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $11.27 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $270 | $3.93 | +6,770.23% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.60 | +1,775.00% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $74.21 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.19 | - | 2 | Jul 21, 2017 |
Vera Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $31.40
Upside: +65.61%
Day One Biopharmaceuticals
Nov 7, 2025
Maintains: Overweight
Price Target: $26 → $27
Current: $10.14
Upside: +166.40%
BridgeBio Pharma
Nov 7, 2025
Maintains: Overweight
Price Target: $76 → $77
Current: $65.65
Upside: +17.29%
Amicus Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $9.27
Upside: +105.07%
Solid Biosciences
Nov 5, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $4.52
Upside: +143.36%
Apellis Pharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $40 → $36
Current: $19.76
Upside: +82.19%
Neurocrine Biosciences
Nov 3, 2025
Maintains: Overweight
Price Target: $171 → $179
Current: $146.88
Upside: +21.87%
Kodiak Sciences
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $19.68
Upside: +21.95%
IDEAYA Biosciences
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $31.54
Upside: +150.48%
Cogent Biosciences
Oct 21, 2025
Maintains: Overweight
Price Target: $30 → $44
Current: $34.23
Upside: +28.54%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $8.86
Upside: +24.15%
Oct 20, 2025
Upgrades: Overweight
Price Target: $13 → $55
Current: $29.55
Upside: +86.13%
Oct 10, 2025
Initiates: Overweight
Price Target: $200
Current: $105.60
Upside: +89.39%
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $32.40
Upside: +14.20%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.01
Upside: -
Aug 14, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $12.59
Upside: +35.03%
Aug 14, 2025
Maintains: Overweight
Price Target: $28 → $29
Current: $8.45
Upside: +243.20%
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $17.80
Upside: +34.87%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $33.59
Upside: +138.17%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $33.18
Upside: +252.62%
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $17.12
Upside: +139.49%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $21.75
Upside: +134.54%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $35.65
Upside: +23.42%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $40.52
Upside: -1.28%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $98.70
Upside: +26.65%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.70
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.69
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $4.23
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.77
Upside: +370.16%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $5.68
Upside: +1,484.51%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $11.69
Upside: +2,039.50%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.68
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $65.65
Upside: -11.65%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $17.52
Upside: -31.51%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $5.70
Upside: +549.69%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $85.09
Upside: -35.36%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $2.52
Upside: +1,013.32%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $43.84
Upside: +23.18%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.70
Upside: +6,328.57%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $18.89
Upside: +42.93%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $449.99
Upside: -69.55%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $8.47
Upside: +466.71%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $11.27
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $225 → $270
Current: $3.93
Upside: +6,770.23%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.60
Upside: +1,775.00%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $74.21
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.19
Upside: -